Edesa Biotech's paridiprubart gains EU orphan drug designation for ARDS
EDSA•Edesa Biotech said paridiprubart received European Commission orphan drug designation for acute respiratory distress syndrome (ARDS). The designation offers reduced development fees and potential market exclusivity after approval.
1. EU designation
Edesa Biotech announced on Nov. 17, 2026, that paridiprubart received European Commission orphan drug designation for ARDS. The company said existing Phase 2/3 results supporting the decision showed improved survival among critically ill patients requiring invasive mechanical ventilation.
2. Potential benefits
The designation provides reduced development fees and potential market exclusivity following approval. Current EU law provides a baseline of 10 years of exclusivity, subject to extensions or reductions; a new scheme takes effect in 2028.




